股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 前海健康控股有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00911 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | 本月底法定/註冊股本總額： ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00911 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | 本月底法定/註冊股本總額： HKD 200,000,000 第 1 頁 共 10 頁 v 1.1.1 截至月份: 2025年12月31日 狀態 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 前海健康控股有限公 司 Qianhai Health Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：911） 截至二零二四年十二月三十一日止年度的 年度業績公告及年報補充公告 茲提述(i)前海健康控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）日期為 二零二三年六月七日的截至二零二二年十二月三十一日止年度（「二零二二財年」） 的年度業績公告及年報的補充公告（「二零二三年公告」）；(ii)本公司截至二零二四年 十二月三十一日止年度（「二零二四財年」）的年度業績公告（「二零二四年年度業績公 告」）；及(iii)本公司二零二四財年的年報（「二零二四年年報」）。除文義另有所指外， 本公告所用詞彙與二零二三年公告、二零二四年年度業績公告及二零二四年年報所 界定者具有相同涵義。 本公司謹此以下列有關虧損合約撥備的資料補充二零二四年年度業績公告及二零 二四年年報。 誠如二零二四 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 前海健康控股有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00911 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | 本月底法定/註冊股本總額 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 本月底法定/註冊股本總額： HKD 200,000,000 第 1 頁 共 10 頁 v 1.1.1 FF301 FF301 致：香港交易及結算所有限公司 公司名稱: 前海健康控股有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00911 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00911 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | 本月底法定/註冊股本總額： HKD 200,000,000 第 1 頁 共 10 頁 v 1.1.1 FF301 FF301 II. 已發行股份及/或 ...

Financial Performance - For the six months ended June 30, 2025, the group recorded revenue of approximately HKD 340.9 million, an increase of about 11% compared to HKD 307.0 million for the previous period[10]. - The gross profit for the interim period decreased to approximately HKD 14.2 million from HKD 42.9 million in the previous period, primarily due to intensified market competition[10]. - The group reported a profit attributable to owners of the company of approximately HKD 4.8 million, down from HKD 15.5 million in the previous period[12]. - Revenue for the six months ended June 30, 2025, was HKD 340,853,000, representing an increase of 11.0% compared to HKD 306,970,000 for the same period in 2024[61]. - Gross profit decreased to HKD 14,155,000 from HKD 42,896,000, indicating a significant decline in profitability[61]. - The company reported a pre-tax operating profit of HKD 4,774,000, down from HKD 15,548,000 in the previous year, reflecting a decrease of 69.4%[61]. - Basic and diluted earnings per share for the period were both HKD 0.0282, compared to HKD 0.0918 for the same period last year, a decline of 69.0%[61]. - The company incurred administrative expenses of HKD 9,371,000 for the six months ended June 30, 2025, compared to HKD 7,406,000 in the previous year, indicating increased operational costs[76]. - Other income for the six months ended June 30, 2025, was HKD 18,000, down from HKD 102,000 in the same period of 2024, reflecting a decline in non-operational revenue sources[78]. Revenue Sources - Approximately 99% of the revenue during this interim period came from the electronic components business, contributing about HKD 339.1 million[10]. - The gross profit for the electronic components segment was HKD 14,059,000, while the health products and food segment contributed HKD 96,000, leading to a total segment profit of HKD 14,155,000, a significant decrease from HKD 42,896,000 in the previous year[74]. Assets and Liabilities - Total assets as of June 30, 2025, were HKD 392,385,000, down from HKD 407,309,000 at the end of 2024, a decrease of 3.7%[62]. - Current assets decreased to HKD 372,073,000 from HKD 386,155,000, reflecting a decline of 3.6%[62]. - The total liabilities decreased to HKD 2,320,000 from HKD 21,739,000, indicating a significant reduction in financial obligations[63]. - The company reported a total equity of HKD 390,065,000 as of June 30, 2025, compared to HKD 385,570,000 at the end of 2024, reflecting a growth in shareholder value[64]. - The company’s total assets less current liabilities stood at HKD 390,489,000 as of June 30, 2025, compared to HKD 385,994,000 at the end of 2024, indicating stable asset management[63]. Cash Flow and Liquidity - The group’s cash and cash equivalents were approximately HKD 27.2 million as of June 30, 2025, up from HKD 23.2 million as of December 31, 2024, demonstrating improved liquidity[20]. - The net cash and cash equivalents at the end of the period increased to HKD 27,181,000 from HKD 2,387,000, showing a positive cash flow trend[65]. - Operating cash flow for the six months ended June 30, 2025, was HKD 4,258,000, a recovery from a cash outflow of HKD 16,758,000 in the same period of 2024[65]. Inventory and Receivables - As of June 30, 2025, the group held inventory of approximately HKD 124.6 million, a decrease from HKD 188.8 million as of December 31, 2024, reflecting effective inventory management[17]. - Trade receivables (net of impairment) increased significantly by approximately 120.8% to about HKD 218.0 million as of June 30, 2025, compared to HKD 98.7 million as of December 31, 2024, indicating continuous sales growth[18]. - The total trade and other receivables increased to HKD 220,331,000 as of June 30, 2025, from HKD 174,146,000 as of December 31, 2024, representing a growth of 26.5%[91]. - The aging analysis of trade receivables showed that amounts overdue by 0 to 30 days increased to HKD 112,743,000 in 2025 from HKD 78,732,000 in 2024, while amounts overdue by 31 to 60 days rose to HKD 105,250,000 from HKD 20,014,000[92]. Strategic Plans and Investments - The group plans to invest in production facilities in China to enhance capacity and provide more services, including technical support and product customization[13]. - The group is actively seeking partnerships with technology companies and research institutions to enhance R&D investment and develop next-generation products[14]. - The group aims to diversify its product and customer base to mitigate market volatility and improve supply chain resilience[14]. Shareholder Information - The company has a total of 89,248,577 shares held by various stakeholders, representing 52.67% ownership[34]. - The total number of issued shares as of June 30, 2025, is 169,445,000 shares[37]. - The new share option plan allows for a maximum issuance of 16,944,500 shares, which is 10% of the total issued ordinary shares as of June 27, 2024[41]. - The new share option plan was approved by shareholders on June 27, 2024, and will last for ten years until June 26, 2034[38]. - The company aims to attract and retain talent through the new share option plan, aligning the interests of participants with those of shareholders[42]. - The maximum number of options that can be granted to any individual participant in a 12-month period is limited to 1% of the total issued shares[44]. - The old share option plan expired on June 8, 2024, and no new options can be granted under that plan[38]. - The company has a significant concentration of ownership, with multiple entities holding the same number of shares, indicating potential governance implications[34]. Legal and Risk Factors - A legal claim was made against the company for an alleged debt of CAD 2.8 million (approximately HKD 14.8 million), but management believes the claim lacks merit and does not expect a significant adverse impact on the financial position[24]. - As of June 30, 2025, the group had no significant contingent liabilities, reflecting a stable risk profile[25]. - The company has not encountered any significant foreign exchange risks due to its monetary assets and liabilities being primarily denominated in HKD and USD, with HKD pegged to USD[23]. - No significant events occurred after the reporting period that would materially affect the group's operations and financial performance[26]. Stock Options and Valuation - The company has not issued, exercised, canceled, or expired any stock options under the new plan during the interim period[49]. - The new stock option plan will be effective for ten years starting June 27, 2024, with approximately nine years remaining as of the report date[49]. - The fair value of the stock options granted was reported at HKD 0.671 to HKD 0.83 per option[52]. - The expected volatility is determined based on the historical volatility of the company's stock price over past years[97]. - The expected term in the model has been adjusted due to factors such as non-transferability, exercise restrictions, and behavior considerations[97]. - The fair value of stock options is estimated using a binomial model[97]. - Variables and assumptions used in calculating the fair value of stock options are based on the best estimates made by the board[97]. - Changes in variables and assumptions may lead to fluctuations in the fair value of stock options[97].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 前海健康控股有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00911 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | III.已發行股份及/或庫存 ...

Core Insights - The company, Qianhai Health (00911), reported a mid-year revenue of approximately HKD 341 million for 2025, reflecting a year-on-year growth of 11.04% [1] - Despite the revenue increase, the net profit decreased to HKD 4.774 million, representing a significant decline of 69.3% compared to the previous period [1] - Earnings per share were reported at HKD 0.0282 [1] Financial Performance - Revenue for the mid-year period reached approximately HKD 341 million, marking an 11.04% increase year-on-year [1] - Gross profit fell from approximately HKD 42.9 million in the previous period to about HKD 14.2 million, indicating a substantial decline [1] - The decrease in gross profit is attributed to intensified market competition, which compelled the company to sell electronic components at lower profit margins [1]

Group 1 - The core viewpoint of the article is that Qianhai Health (00911) reported a revenue increase of approximately HKD 341 million for the first half of 2025, reflecting a year-on-year growth of 11.04% [1] - Despite the revenue growth, the company's net profit decreased to HKD 4.774 million, representing a significant year-on-year decline of 69.3% [1] - The gross profit for the period fell from approximately HKD 42.9 million in the previous period to about HKD 14.2 million, primarily due to intensified market competition leading to lower gross margins on electronic component sales [1]